Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
78Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $180.46M | $20.20M | $0.38 |
| 2024 | $160.95M | $14.46M | $0.25 |
| 2023 | $142.52M | $8.28M | $0.17 |
| 2022 | $129.34M | $-2.32M | $-0.05 |
| 2021 | $103.64M | $-2.23M | $-0.05 |
Social Signal Score
Earnings
Mon, Nov 9(in 3 months)
Consensus estimate $0.13 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.16 vs $0.11beat
- Wed, May 13$0.07 vs $0.12miss
- Wed, Mar 11$0.06 vs $0.09miss
- Mon, Nov 10$0.09 vs $0.10miss
- Wed, Aug 13$0.13 vs $0.09beat
- Wed, May 14$0.07 vs $0.07beat
Estimates and results for KMDA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.51
- Implied price
- $9.78
- Return from $7.58
- 5.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.86 — -35.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| -2.0% | -11.5% | -7.7% | -4.5% | -1.7% | 0.9% |
| 3.0% | -7.0% | -3.0% | 0.4% | 3.3% | 6.0% |
| 8.0% | -2.5% | 1.7% | 5.2% | 8.4% | 11.2% |
| 13.0% | 2.1% | 6.4% | 10.1% | 13.4% | 16.3% |
| 18.0% | 6.6% | 11.1% | 15.0% | 18.4% | 21.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (6)
- Newszacks.com·1d ago·Positive
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes" Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·1d ago·Positive
KMDA or PRTA: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·3d ago·Neutral
Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsglobenewswire.com·3d ago·Positive
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced fi
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Kamada Announces Planned Transition of Chief Financial Officer REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that Chaime Orlev, its Chief Financial Officer (CFO), will transition out of his role to pursue other opportunities, effective Dece
View source ↗